Background {#Sec1}
==========

In China, gastric cancer is the third most common cancer and the second leading cause of cancer-related death \[[@CR1]\]. And most patients with gastric cancer are diagnosed with an advanced stage of the disease in China, some even with metastatic disease \[[@CR2], [@CR3]\]. Peritoneal dissemination is the most common manifestation for late-stage gastric cancer \[[@CR4]\]. The prognosis of patients who have gastric cancer with peritoneal dissemination is very poor, even with the development of targeted therapy and chemotherapy \[[@CR5], [@CR6]\]. Palliative gastrectomy is still controversial for this group of patients. In clinic, we believed that the nutritional status is an important factor that impacts the treatment and prognosis of patients who have gastric cancer with peritoneal dissemination.

Body mass index (BMI) is commonly used to assess nutritional status \[[@CR7]\]. According to the World Health Organization's (WHO) guidelines, BMI is divided into three groups with 18.5 and 25 as the cutoff values for a normal BMI level. However, in Asia, a BMI range of 18.5 to 23 is always used to classify people into the underweight group, normal range group, and overweight group \[[@CR8]\]. BMI has always been used as an indicator of the status of patients. It had been reported that the BMI would infect the surgical outcomes in colorectal cancer, pancrea cancer, liver cancer, and so on. \[[@CR9]--[@CR13]\]. However, the controversy of the BMI on perioperative morbidity still remained \[[@CR14]--[@CR17]\]. In a report by Pawlik et al. about the BMI and gastric cancer, the overall survival of patients with underweight patients with a BMI \<18.5 kg/m^2^ after gastrectomy for cancer was worse than those with BMI higher than 18.5 \[[@CR18]\]. Hu et al. reported that a low BMI was associated with more severe postoperative complications and a poor prognosis, compared to patients with a normal BMI \[[@CR19]\]. However, there are no reports in the current literature that have examined the relationship between BMI and the prognosis of patients who have gastric cancer with peritoneal dissemination.

The aim of our study was to examine the relationship between BMI and the prognosis of gastric cancer patients who have peritoneal dissemination.

Methods {#Sec2}
=======

Ethics approval and consent {#Sec3}
---------------------------

All patients provided written informed consent for their information to be stored in a hospital database. A separate consent was obtained for the use of this information for research purposes. Study approval was obtained from independent ethics committees at the Sixth Affiliated Hospital of Sun Yat-Sen University. This study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

Patients {#Sec4}
--------

Between January 2000 and April 2014, a total of 518 patients were histologically proven and diagnosed with gastric adenocarcinoma with peritoneal metastasis in surgery in The Sixth Affiliated Hospital of Sun Yat-sen University and Sun Yat-sen University Cancer Center. Patients were divided into three groups based on their BMI using 18.5 and 23 as the cutoff values. The clinicopathologic characteristics and clinical outcomes of all 518 patients were reviewed.

Patient inclusion criteria {#Sec5}
--------------------------

The inclusion criteria were as follows: (1) WHO performance status of 0 to 1; (2) the patient underwent surgery and had histologically proven gastric adenocarcinoma of the stomach with peritoneal dissemination; (3) no synchronous or metachronous cancers; (4) no history of previous radiotherapy or other treatments, including immunotherapy or traditional Chinese medicine; and (5) no prior gastric surgery.

Classification of peritoneal seeding {#Sec6}
------------------------------------

According to the first English edition of the Japanese classification of gastric carcinoma, the degree of peritoneal metastasis was classified as follows: P0, no peritoneal dissemination or seeding; P1, disseminating metastasis to the region directly adjacent to the peritoneum of the stomach (above the transverse colon including the greater omentum); P2, several scattered metastases to the distant peritoneum and ovarian metastasis alone; and P3, numerous metastases to the distant peritoneum \[[@CR20]\].

Follow-up {#Sec7}
---------

Following treatment, patients were monitored every month for the first year, every 3 months for the second year, and every 6 months thereafter. Telephone calls and letters were used to follow-up patients who were unable to attend regular follow-up assessments. Complete data were collected for all 523 patients through December 2015.

Statistical methods {#Sec8}
-------------------

A chi-square test was used to compare the categorical variables between the palliative operative group and the other groups. Student's *t* test was used to compare continuous variables. Univariate survival analyses were performed using Kaplan-Meier methods. Survival curves were compared using the log-rank test. Analyses were performed using SPSS software v.20.0 (SPSS, Inc., Chicago, IL) for Windows. Statistical significance was defined as *p* \< 0.05.

Results {#Sec9}
=======

Patient demographics {#Sec10}
--------------------

Among the 518 patients with gastric cancer and peritoneal dissemination, 330 underwent non-curative gastrectomy, while 188 patients did not. Their median age was 59 years (range, 18--83). Of these patients, 289 were male and 229 were female. The 1-year overall survival of the entire cohort was 26.0%, with a median survival of 13.2 months. Patients were separated into three groups based on their BMI with the cutoff values of 18.5 and 23. There were 167 patients with a BMI \<18.5, 232 with a BMI 18.5--23, and 119 patients with a BMI \>23. The patient clinicopathological characteristics are presented in Table [1](#Tab1){ref-type="table"}.Table 1Clinical pathological data for gastric cancer patients with different BMI groupsClinical pathological dataFewer than 18.5 (*n* = 167 cases)Between 18.5--23\
(*n* = 232 cases)Greater than 23 (*n* = 119 cases)*p* valueCases%Cases%Cases%Age (years)Mean52.652.953.3--Range20--8519--8529--84SexMale9556.912252.67260.5Female7243.111047.44739.50.347Tumor locationGastric cardia4024.04720.33126.1Middle2615.64720.33226.9Antrum6337.79239.73630.3Total stomach3822.84619.82016.80.181SurgeryGastrectomy9053.916571.17563.0No gastrectomy7746.16728.94437.00.002Tumor size\<5 cm5029.99139.24739.5≥5 and \<10 cm8349.710444.85647.1≥10 cm3420.43715.91613.40.249Serum CEA level\<5 ng/ml10467.516573.78070.8≥5 ng/ml5032.55926.33329.20.433CA19-9 level\<35 U/ml9159.915169.37263.7≥35U/ml6140.16730.74136.30.166Seeding grade^a^P12816.86628.44235.3P24426.37231.03327.7P39556.99440.54437.00.001Multi-site metastasisWithout9758.118178.08168.1With7041.95122.03831.9\< 0.001ChemotherapyWithout7746.16829.33630.3With9053.916470.78369.70.001^a^Peritoneal dissemination grade was divided into P1, P2, and P3 groups under the standard of first English version of Japanese classification of gastric carcinoma

Univariate analyses of the prognosis of this group of gastric cancer patients with peritoneal dissemination {#Sec11}
-----------------------------------------------------------------------------------------------------------

Based on Kaplan-Meier analysis, palliative gastrectomy (*p* \< 0.001), tumor size (*p* \< 0.001), tumor location (*p* = 0.011), peritoneal seeding grade (*p* \< 0.001), ascites (*p* = 0.001), serum CEA level (*p* = 0.002), serum CA19-9 level (*p* = 0.033), palliative chemotherapy (*p* \< 0.001), and BMI group (*p* \< 0.001) were significant prognostic factors in this cohort, and the results were shown in Fig. [1](#Fig1){ref-type="fig"}. As shown in Table [2](#Tab2){ref-type="table"}, the median survival of patients based on BMI were 8.17 months in patients with a BMI less than 18.5, 18.67 months for those with a BMI between 18.5 and 23, and 11.87 months in patients with a BMI greater than 23.Fig. 1The Kaplan-Meier analysis of the prognosis of this group of gastric cancer patients with peritoneal dissemination. Palliative gastrectomy (**a**), tumor size (**b**), tumor location (**c**), peritoneal seeding grade (**d**), ascites (**e**), serum CEA level (**f**), serum CA19-9 level (**g**), palliative chemotherapy (**h**), and BMI group (**i**) were significant prognostic factors in this cohort Table 2Univariate analysis of the overall survival in these group gastric cancer patients with peritoneal disseminationVariables*n*1-year survival rate (%)Median survival (months)*p* valueAll 518 gastric cancer patients with peritoneal dissemination Palliative gastrectomy\<0.001  With330197.33  Without1883116.13 Tumor size\<0.001  \<5 cm1883117.30  5 and \<10 cm2432611.00  \>10 cm87189.30 Tumor location0.011  Upper1182312.00  Middle1053015.60  Lower1913913.33  Total104208.97 Peritoneal seeding grade\<0.001  P11363418.67  P21493115.48  P3233198.97 Ascite0.001  With207209.87  Without3113114.27 Serum CEA level (ng/ml)0.002  Normal3492914.03  Elevated142209.33 Serum CA19-9 level (U/ml)0.033  Normal3142913.53  Elevated1692211.27 Palliative chemotherapy\<0.001  Yes3373517.40  No18196.90 BMI group (kg/m^2^)\<0.001  \<18.5167158.17  18.5--232323518.67  \>231192511.87

BMI value was an independent prognostic factor of gastric cancer patients with peritoneal dissemination by multivariate analyses {#Sec12}
--------------------------------------------------------------------------------------------------------------------------------

Cox regression model was used to identify the independent prognostic risk factors in patients with gastric cancer and peritoneal seeding. The results revealed that palliative gastrectomy, peritoneal seeding grade, serum CEA level, palliative chemotherapy, and BMI value were independent prognostic risk factors. All of these results are presented in Table [3](#Tab3){ref-type="table"}.Table 3Multivariate analyses of the overall survival in gastric cancer patients (Cox regression model)VariableHR95% CI*p* valueOS in gastric cancer patients Palliative gastrectomy\
 (Gastrectomy vs. without gastrectomy)^a^0.6890.540--0.8790.003 Tumor size\
 (\<5, ≥5, and \<10 vs. ≥10 cm)1.1760.999--1.3830.051 Tumor location\
 (Upper, middle, and lower vs. total)1.0800.962--1.2130.192 Ascite\
 (With vs. without)1.0260.817--1.2880.827 Peritoneal seeding grade\
 (P1 and P2 vs. P3)1.2981.124--1.500\< 0.001 Serum CEA Level\
 (Normal vs. elevated)1.4241.120--1.8100.004 Serum CA19-9 Level\
 (Normal vs. elevated)1.1330.900--1.4240.287 Palliative chemotherapy\
 (With vs. without)0.3990.314--0.506\< 0.001 BMI group\
 (\<18.5 and 18.5--23 vs. \>23)0.8120.686--0.9620.016Abbreviations: *OS* overall survival, *HR* hazard ratio, *CI* confidence interval^a^The factor listed at the last was used as the control level in this Cox regression model

Univariate analyses and multivariate analysis of the prognosis of gastric cancer patients with peritoneal dissemination without palliative chemotherapy {#Sec13}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Patients were stratified based on having received palliative chemotherapy or not. Kaplan-Meier analysis showed that palliative gastrectomy (*p* \< 0.001), tumor size (*p* = 0.049), tumor location (*p* = 0.002), peritoneal seeding grade (*p* \< 0.001), ascites (*p* = 0.017), serum CEA level (*p* = 0.024), serum CA19-9 level (*p* = 0.014), and BMI group (*p* = 0.008) were prognostic risk factors. All of these results are presented in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2The Kaplan-Meier analysis of the prognosis of this group of gastric cancer patients with peritoneal dissemination without palliative chemotherapy. Palliative gastrectomy (**a**), tumor size (**b**), tumor location (**c**), peritoneal seeding grade (**d**), ascites (**e**), serum CEA level (**f**), serum CA19-9 level (**g**), and BMI group (**h**) were prognostic risk factors

Only the tumor location and the peritoneal seeding grade remained independent prognostic factors upon Cox regression analysis, as shown in Table [4](#Tab4){ref-type="table"}.Table 4Multivariate analyses of the overall survival in these group gastric cancer patients with peritoneal dissemination without palliative chemotherapy (Cox regression model)VariableHR95% CI*p* valueOS in gastric cancer patients Palliative gastrectomy\
 (Gastrectomy vs. without gastrectomy)^a^0.7720.516--1.1540.207 Tumor size\
 (\<5, ≥5, and \<10 vs. ≥10 cm)1.0160.771--1.3390.910 Tumor location\
 (Upper, middle, and lower vs. total)1.3141.070--1.6140.009 Ascite\
 (With vs. without)0.9690.653--1.4380.877 Peritoneal seeding grade\
 (P1 and P2 vs. P3)1.5071.178--1.9280.001 Serum CEA Level\
 (Normal vs. elevated)1.3560.915--2.0110.129 Serum CA19-9 Level\
 (Normal vs. elevated)1.3840.943--2.0310.097 BMI group\
 (\<18.5 and 18.5--23 vs. \>23)0.8710.654--1.1610.346Abbreviations: *OS* overall survival, *HR* hazard ratio, *CI* confidence interval^a^The factor listed at the last was used as the control level in this Cox regression model

Univariate analyses and multivariate analysis of the prognoses of gastric cancer patients with peritoneal dissemination with palliative chemotherapy {#Sec14}
----------------------------------------------------------------------------------------------------------------------------------------------------

As shown in Fig. [3](#Fig3){ref-type="fig"}, 337 patients received palliative chemotherapy in this cohort. Results from Kaplan-Meier analysis showed that the palliative gastrectomy (*p* \< 0.001), tumor size (*p* = 0.002), tumor location (*p* = 0.024), peritoneal seeding grade (*p* = 0.008), serum CEA level (*p* = 0.041), and BMI group (*p* \< 0.001) were risk factors.Fig. 3The Kaplan-Meier analysis of the prognosis of this group of gastric cancer patients with peritoneal dissemination underwent palliative chemotherapy. Palliative gastrectomy (**a**), tumor size (**b**), tumor location (**c**), peritoneal seeding grade (**d**), serum CEA level (**e**), and BMI group (**f**) were risk factors

Multivariate analysis showed that palliative gastrectomy, serum CEA level, and BMI group were independent prognostic factors, as showed in Table [5](#Tab5){ref-type="table"}.Table 5Multivariate analyses of the overall survival in these group gastric cancer patients with peritoneal dissemination with palliative chemotherapy (Cox regression model)VariableHR95% CI*p* valueOS in gastric cancer patients Palliative gastrectomy\
 (Gastrectomy vs. without gastrectomy)^a^0.6520.477--0.8930.008 Tumor size\
 (\<5, ≥5, and \<10 vs. ≥10 cm)1.2651.027--1.5590.027 Tumor location\
 (Upper, middle, and lower vs. total)0.9720.844--1.1180.689 Peritoneal seeding grade\
 (P1 and P2 vs. P3)1.1720.982--1.3980.079 Serum CEA level\
 (Normal vs. elevated)1.4131.045--1.9120.025 BMI group\
 (\<18.5 and 18.5--23 vs. \>23)0.7830.636--0.9640.021Abbreviations: *OS* overall survival, *HR* hazard ratio, *CI* confidence interval^a^The factor listed at the last was used as the control level in this Cox regression model

Discussion {#Sec15}
==========

With the increasing prevalence of obesity that occurred in China and worldwide \[[@CR21]\], few recent reports have concluded that some classes of obesity can be considered "healthy." Findings from our study show that BMI value was an independent prognostic factor for patients who have gastric carcinoma with peritoneal seeding. Patients with low BMI as well as a high BMI had a worse survival rate compared with patients who had a BMI within normal range. Previous studies have reported that patients with higher BMI would be at higher risk for perioperative morbidity after major abdominal cancer surgery \[[@CR16], [@CR22]\]. In the study from Memorial Sloan-Kettering Cancer Center, the results showed that higher BMI of the patients (higher than 25) would bring longer operative time, fewer lymph nodes, and higher complications \[[@CR15]\]. In our study, a higher ratio of the patients with a normal BMI underwent palliative gastrectomy, which is an important independent prognostic factor, in addition to palliative chemotherapy.

However, the function of palliative gastrectomy remains controversial, especially for the patients with peritoneal dissemination. Some studies have suggested that palliative gastrectomy may improve survival without increasing morbidity and mortality \[[@CR23], [@CR24]\], while other reports have contradicted this suggestion \[[@CR2], [@CR25]\]. Selection of patients for palliative gastrectomy remains controversial for both surgeons and oncologists. In our studies, we stratified the 518 patients based on receipt of palliative chemotherapy to eliminate the influences of the palliative chemotherapy. Among the patients who did not receive palliative chemotherapy, neither palliative gastrectomy nor BMI was independent prognostic factors. Conversely, among patients who received palliative chemotherapy, both palliative gastrectomy and BMI were independent prognostic factors. This finding implies that patients with a normal BMI who receive palliative chemotherapy may benefit from gastrectomy.

As a retrospective study, there were confounding factors that may have influenced the statistical analyses and conclusions. BMI is an important factor that reflects the nutritional status and is correlated with postoperative complications and long-term survival of gastric cancer. Findings from this study suggest that gastric cancer patients with a normal BMI may benefit from palliative gastrectomy combined with chemotherapy. Additional experiments and clinical trials are needed to validate the important value of BMI on the prognosis of gastric cancer patients with peritoneal dissemination.

Conclusions {#Sec16}
===========

BMI is a prognostic factor for patients who have gastric cancer with peritoneal dissemination, especially in those who received palliative chemotherapy. BMI can be used to predict the effect of palliative chemotherapy on these patients.
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